CliffBio
small molecule

OXILAN-300

IOXILAN

Loss of exclusivity—loss of exclusivity
CompanyGuerbet →See this company's full patent-cliff portfolio

Drug detail

Brand nameOXILAN-300
Active ingredientIOXILAN
Strength62%
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalDecember 1995
Marketing statusDISCN

More from Guerbet

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

OXILAN-300 patent cliff — loss of exclusivity — | CliffBio